Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors.
Protein arginine methyltransferase 5 (PRMT5) is the primary type II methyltransferase that mainly catalyzes symmetric demethylation of arginine residues in both histone and nonhistone proteins.
APA
Song P, Yang F (2026). Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors.. Genes & diseases, 13(1), 101796. https://doi.org/10.1016/j.gendis.2025.101796
MLA
Song P, et al.. "Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors.." Genes & diseases, vol. 13, no. 1, 2026, pp. 101796.
PMID
41078957
Abstract
Protein arginine methyltransferase 5 (PRMT5) is the primary type II methyltransferase that mainly catalyzes symmetric demethylation of arginine residues in both histone and nonhistone proteins. Increasing evidence has demonstrated that PRMT5 is indispensable in tumorigenesis and acquired therapeutic resistance in multiple malignancies. This review summarizes the clinical significance of PRMT5 in solid tumors such as lung cancer, breast cancer, and glioblastoma, its role in tumor immunology, and current clinical trials of PRMT5 inhibitors, and discusses the clinical status, current dilemma, and future perspectives of PRMT5 inhibition as a novel therapeutic strategy.
같은 제1저자의 인용 많은 논문 (5)
- Retraction notice to "GE11-modified carboxymethyl chitosan micelles to deliver DOX·PD-L1 siRNA complex for combination of ICD and immune escape inhibition against tumor" [Carbohydrate Polymers 312 (2023) 120837].
- Impact of Adjuvant Chemotherapy on Survival of the Patients with pT1N + M0 Gastric Cancer: A Retrospective Cohort Study.
- HSF1 promotes malignant phenotype in colorectal cancer via super-enhancer-driven lncRNA EXOSC10-AS1 and targeting HSF1 confers sensitivity to poly (ADP-ribose) polymerase inhibitor Niraparib.
- RXRG as a Novel Biomarker and its Correlation With Immune Infiltration in Thyroid Carcinoma.
- Prospects and Challenges of Immunotherapy for Thyroid Cancer.